Bayer CropScience Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: October 3, 2025, 11:51 pm

Quick Insight

Bayer CropScience Ltd currently trades at ₹5,245 with a market capitalization of ₹23,556 Cr. The company's Price-to-Earnings ratio stands at 39.8, showcasing a premium valuation compared to the industry average of around 25 in India. Notably, Bayer CropScience boasts a Return on Equity of 20.0%, surpassing the sector norm of 15-18%. Its Return on Capital Employed at 24.8% also outperforms peers, indicating efficient capital utilization. With a healthy Operating Profit Margin of 18%, the company demonstrates strong operational efficiency. However, the high Price-to-Book Value ratio of 7.76x may deter value investors, as it exceeds the sector average of approximately 5x.

One key strength of Bayer CropScience lies in its robust financial position, with significant reserves of ₹2,806 Cr and a comfortable Interest Coverage Ratio of 47.61x, signaling the ability to service debt obligations comfortably. Moreover, the company's high promoter holding of 71.44% underscores confidence in its long-term prospects. On the flip side, risks include the extended Cash Conversion Cycle of 234 days, which may indicate inefficiencies in working capital management, potentially impacting liquidity. Additionally, the relatively low foreign institutional ownership at 3.64% could limit the stock's exposure to international investors. Looking ahead, enhancing operational efficiencies and reducing the Cash Conversion Cycle could bolster profitability and investor appeal, while addressing foreign investor participation could improve market sentiment and liquidity.

In conclusion, while Bayer CropScience exhibits strong financial performance and operational metrics, investors should carefully monitor working capital efficiency and international investor interest. Addressing these areas could further enhance the company's competitive positioning and attractiveness to a broader investor base.

Competitors of Bayer CropScience Ltd

All Competitor Stocks of Bayer CropScience Ltd

Quarterly Result

Last Updated: August 19, 2025, 10:35 pm

Below is a detailed analysis of the quarterly data for Bayer CropScience Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 1,915.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,046.00 Cr. (Mar 2025) to 1,915.00 Cr., marking an increase of 869.00 Cr..
• For Expenses, as of Jun 2025, the value is 1,566.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 876.00 Cr. (Mar 2025) to 1,566.00 Cr., marking an increase of 690.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 348.00 Cr.. The value appears strong and on an upward trend. It has increased from 171.00 Cr. (Mar 2025) to 348.00 Cr., marking an increase of 177.00 Cr..
• For OPM %, as of Jun 2025, the value is 18.00%. The value appears strong and on an upward trend. It has increased from 16.00% (Mar 2025) to 18.00%, marking an increase of 2.00%.
• For Other Income, as of Jun 2025, the value is 19.00 Cr.. The value appears to be declining and may need further review. It has decreased from 37.00 Cr. (Mar 2025) to 19.00 Cr., marking a decrease of 18.00 Cr..
• For Interest, as of Jun 2025, the value is 5.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 6.00 Cr. (Mar 2025) to 5.00 Cr., marking a decrease of 1.00 Cr..
• For Depreciation, as of Jun 2025, the value is 27.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 34.00 Cr. (Mar 2025) to 27.00 Cr., marking a decrease of 7.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 335.00 Cr.. The value appears strong and on an upward trend. It has increased from 168.00 Cr. (Mar 2025) to 335.00 Cr., marking an increase of 167.00 Cr..
• For Tax %, as of Jun 2025, the value is 17.00%. The value appears to be increasing, which may not be favorable. It has increased from 15.00% (Mar 2025) to 17.00%, marking an increase of 2.00%.
• For Net Profit, as of Jun 2025, the value is 279.00 Cr.. The value appears strong and on an upward trend. It has increased from 143.00 Cr. (Mar 2025) to 279.00 Cr., marking an increase of 136.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 62.01. The value appears strong and on an upward trend. It has increased from 31.89 (Mar 2025) to 62.01, marking an increase of 30.12.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 2:39 pm

Growth

Last Updated: September 5, 2025, 2:36 pm

Balance Sheet

Last Updated: August 11, 2025, 3:27 pm

Below is a detailed analysis of the balance sheet data for Bayer CropScience Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 45.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 45.00 Cr..
• For Reserves, as of Mar 2025, the value is 2,806.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,804.00 Cr. (Mar 2024) to 2,806.00 Cr., marking an increase of 2.00 Cr..
• For Borrowings, as of Mar 2025, the value is 105.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 47.00 Cr. (Mar 2024) to 105.00 Cr., marking an increase of 58.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 2,290.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,701.00 Cr. (Mar 2024) to 2,290.00 Cr., marking an increase of 589.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 5,246.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4,597.00 Cr. (Mar 2024) to 5,246.00 Cr., marking an increase of 649.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 470.00 Cr.. The value appears strong and on an upward trend. It has increased from 414.00 Cr. (Mar 2024) to 470.00 Cr., marking an increase of 56.00 Cr..
• For CWIP, as of Mar 2025, the value is 119.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 119.00 Cr..
• For Investments, as of Mar 2025, the value is 35.00 Cr.. The value appears to be declining and may need further review. It has decreased from 54.00 Cr. (Mar 2024) to 35.00 Cr., marking a decrease of 19.00 Cr..
• For Other Assets, as of Mar 2025, the value is 4,622.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,010.00 Cr. (Mar 2024) to 4,622.00 Cr., marking an increase of 612.00 Cr..
• For Total Assets, as of Mar 2025, the value is 5,246.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,597.00 Cr. (Mar 2024) to 5,246.00 Cr., marking an increase of 649.00 Cr..

Notably, the Reserves (2,806.00 Cr.) exceed the Borrowings (105.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Bayer CropScience Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 126.38. This value is within the healthy range. It has decreased from 164.77 (Mar 24) to 126.38, marking a decrease of 38.39.
• For Diluted EPS (Rs.), as of Mar 25, the value is 126.38. This value is within the healthy range. It has decreased from 164.77 (Mar 24) to 126.38, marking a decrease of 38.39.
• For Cash EPS (Rs.), as of Mar 25, the value is 145.41. This value is within the healthy range. It has decreased from 181.40 (Mar 24) to 145.41, marking a decrease of 35.99.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 634.83. It has increased from 634.61 (Mar 24) to 634.83, marking an increase of 0.22.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 634.83. It has increased from 634.61 (Mar 24) to 634.83, marking an increase of 0.22.
• For Dividend / Share (Rs.), as of Mar 25, the value is 125.00. This value exceeds the healthy maximum of 3. It has decreased from 140.00 (Mar 24) to 125.00, marking a decrease of 15.00.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 1,219.02. It has increased from 1,136.57 (Mar 24) to 1,219.02, marking an increase of 82.45.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 180.24. This value is within the healthy range. It has decreased from 230.51 (Mar 24) to 180.24, marking a decrease of 50.27.
• For PBIT / Share (Rs.), as of Mar 25, the value is 161.34. This value is within the healthy range. It has decreased from 214.03 (Mar 24) to 161.34, marking a decrease of 52.69.
• For PBT / Share (Rs.), as of Mar 25, the value is 157.55. This value is within the healthy range. It has decreased from 209.66 (Mar 24) to 157.55, marking a decrease of 52.11.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 126.50. This value is within the healthy range. It has decreased from 164.92 (Mar 24) to 126.50, marking a decrease of 38.42.
• For PBDIT Margin (%), as of Mar 25, the value is 14.78. This value is within the healthy range. It has decreased from 20.28 (Mar 24) to 14.78, marking a decrease of 5.50.
• For PBIT Margin (%), as of Mar 25, the value is 13.23. This value is within the healthy range. It has decreased from 18.83 (Mar 24) to 13.23, marking a decrease of 5.60.
• For PBT Margin (%), as of Mar 25, the value is 12.92. This value is within the healthy range. It has decreased from 18.44 (Mar 24) to 12.92, marking a decrease of 5.52.
• For Net Profit Margin (%), as of Mar 25, the value is 10.37. This value exceeds the healthy maximum of 10. It has decreased from 14.51 (Mar 24) to 10.37, marking a decrease of 4.14.
• For Return on Networth / Equity (%), as of Mar 25, the value is 19.92. This value is within the healthy range. It has decreased from 25.98 (Mar 24) to 19.92, marking a decrease of 6.06.
• For Return on Capital Employeed (%), as of Mar 25, the value is 23.96. This value is within the healthy range. It has decreased from 32.03 (Mar 24) to 23.96, marking a decrease of 8.07.
• For Return On Assets (%), as of Mar 25, the value is 10.82. This value is within the healthy range. It has decreased from 16.10 (Mar 24) to 10.82, marking a decrease of 5.28.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 1.11. It has increased from 1.10 (Mar 24) to 1.11, marking an increase of 0.01.
• For Current Ratio (X), as of Mar 25, the value is 2.01. This value is within the healthy range. It has decreased from 2.44 (Mar 24) to 2.01, marking a decrease of 0.43.
• For Quick Ratio (X), as of Mar 25, the value is 0.94. This value is below the healthy minimum of 1. It has decreased from 1.48 (Mar 24) to 0.94, marking a decrease of 0.54.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.84. This value is below the healthy minimum of 4. It has increased from 1.48 (Mar 24) to 1.84, marking an increase of 0.36.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 81.93 (Mar 24) to 0.00, marking a decrease of 81.93.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 74.48 (Mar 24) to 0.00, marking a decrease of 74.48.
• For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 18.07 (Mar 24) to 0.00, marking a decrease of 18.07.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 25.52 (Mar 24) to 0.00, marking a decrease of 25.52.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 47.61. This value is within the healthy range. It has decreased from 52.81 (Mar 24) to 47.61, marking a decrease of 5.20.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 34.41. This value is within the healthy range. It has decreased from 38.78 (Mar 24) to 34.41, marking a decrease of 4.37.
• For Enterprise Value (Cr.), as of Mar 25, the value is 21,230.10. It has decreased from 22,377.29 (Mar 24) to 21,230.10, marking a decrease of 1,147.19.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.88. This value exceeds the healthy maximum of 3. It has decreased from 4.38 (Mar 24) to 3.88, marking a decrease of 0.50.
• For EV / EBITDA (X), as of Mar 25, the value is 26.23. This value exceeds the healthy maximum of 15. It has increased from 21.62 (Mar 24) to 26.23, marking an increase of 4.61.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.04. This value exceeds the healthy maximum of 3. It has decreased from 4.61 (Mar 24) to 4.04, marking a decrease of 0.57.
• For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 18.06 (Mar 24) to 0.00, marking a decrease of 18.06.
• For Price / BV (X), as of Mar 25, the value is 7.76. This value exceeds the healthy maximum of 3. It has decreased from 8.26 (Mar 24) to 7.76, marking a decrease of 0.50.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.04. This value exceeds the healthy maximum of 3. It has decreased from 4.61 (Mar 24) to 4.04, marking a decrease of 0.57.
• For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.02, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness